Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Size: px
Start display at page:

Download "Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:"

Transcription

1 The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product. Before prescribing any product mentioned in this Register, healthcare professionals should consult prescribing information for the product approved in their country. Study No.: BEX (formerly CP ) Title: Phase II study of Iodine-131 anti-b1 antibody for 1st or 2nd relapsed indolent B-cell lymphomas or B-cell lymphomas that have transformed to a more aggressive histology Rationale: The rationale for this clinical trial was based on results of previous trials indicating that chemotherapyrefractory patients with few or no options for therapy responded well to Iodine-131 Anti B1 Antibody (hereafter referred to as tositumomab and iodine I 131 tositumomab). This study was designed to establish the safety and efficacy profile of tositumomab and iodine I 131 tositumomab in patients with 1st or 2nd relapsed indolent B cell lymphomas or B cell lymphomas that had transformed to a more aggressive histology. Phase: II Study Period: 02 July 1998 to 21 April 2011 Study Design: Study BEX was designed as a single-arm, open label study that evaluated subjects treated with tositumomab and iodine I 131 tositumomab for safety and efficacy until the subject s disease progressed, the subject died, or the subject was on study for 2 years, whichever occurred first. Subjects who completed 2 years of Study BEX were eligible to enter Study BEX for long-term follow-up (LTFU) evaluations. All surviving subjects were assessed for survival and disease status, including subsequent therapy for NHL, and for long-term safety, including the use of thyroid medication, development of hypothyroidism, myelodysplastic syndrome (MDS), acute myelogenous leukemia (AML), and all other secondary malignancies. Additionally, these subjects were assessed for the development of any adverse event(s) deemed by the Principal Investigator as being possibly or probably related to the subject s previous treatment with tositumomab and iodine I 131 tositumomab. Laboratory evaluations consisted of thyroid stimulating hormone (TSH) levels and complete blood cell (CBC) counts with differential and platelet count. Subjects were followed for continued response and safety every six months for years 3 through 5 post treatment. Beginning at year six, all subjects were assessed annually through year 10 inclusive. Centres: St. Bartholomew s Hospital, United Kingdom and Christie Hospital NHS Trust, United Kingdom Indication: non-hodgkin s B Cell Lymphoma (NHL) Treatment: Subjects underwent 2 phases of study. In the first phase (dosimetric dose), subjects received an infusion of unlabeled tositumomab (450 mg) followed by tositumomab (35 mg) labeled with 5 mci of Iodine 131. Using the total body residence time derived from gamma counts obtained at the 3 imaging timepoints, a subject-specific dose of iodine 131 tositumomab was calculated to deliver the desired total body dose of radiotherapy. In the second phase, (therapeutic dose), subjects received tositumomab (450 mg) followed 35 mg tositumomab labeled with the subjectspecific dose of Iodine 131 to deliver a total body dose of 75 cgy. Subjects with platelet counts of 100, ,999 cells/mm 3 received 65 cgy, and obese subjects were dosed based upon 137% of their lean body mass. For thyroid protection, subjects were treated with either saturated solution potassium iodide (SSKI), Lugol s solution, or potassium iodide tablets starting at least 24 hours prior to the dosimetric dose and continuing for 14 days following the therapeutic dose. Objectives: To establish the response rate, duration of response, time to progression, time to treatment failure, and survival after treatment with tositumomab and iodine I 131 tositumomab in patients with 1st or 2nd relapsed indolent or transformed non-hodgkin's B-cell lymphoma. Primary Outcome/Efficacy Variable: The primary efficacy endpoint of the study was the response rate (CR+CCR+PR). Secondary Outcome/Efficacy Variables: The secondary efficacy endpoints were the duration of response, time to progression, time-to-treatment failure, safety, and survival. Statistical Methods: Analyses were performed using data from all enrolled subjects (intent-to-treat [ITT]). The response rate was estimated from objective evidence of tumor response or progression. Measurable lesions were defined as any lesion >2 cm in both perpendicular diameters at baseline, and response to therapy was assessed by the following criteria. Complete Response (CR): Complete resolution of all disease-related radiological abnormalities and disappearance of all signs and symptoms related to the disease. Clinical Complete Response (CCR): Complete resolution of all disease-related symptoms but residual focal abnormality which was thought to be residual scar tissue. Partial Response (PR): Greater than or equal to a 50% reduction in the sum of the products of the longest perpendicular diameters of all measurable lesions with no new lesions. Stable Disease (SD): Less than a 25% increase and less than a 50% decrease in the sum of the products of the 1

2 longest perpendicular diameters of all measurable lesions with no new lesions. Progressive Disease (PD): Greater than or equal to a 25% increase from the nadir value of the sum of the products of the longest perpendicular diameters of all measurable lesions. Two-sided 95% confidence intervals (95% CIs) were calculated. Long-term efficacy analyses included analyses of duration of response, time to progression or death (i.e., progression-free survival) and Kaplan-Meier analysis of overall survival. Long-term safety analyses included analyses of the cumulative incidence of HAMA positivity, the cumulative incidence of hypothyroidism, the cumulative incidence of MDS/AML, tabulation of deaths and analyses of other longterm adverse events including secondary malignancies. Study Population: Male or female subjects at least 18 years of age with a histologically confirmed diagnosis of B-cell CLL/PLL/SLL; lymphoplasmacytic - immunocytoma; follicle center, follicular, Grade I; follicle center, follicular, Grade II NHL; or one of these B-cell lymphomas which had transformed to a more aggressive histology were eligible for enrollment. Evidence of CD20 expression by tumor tissue was required. Subjects must have received 1 or 2 prior chemotherapy regimens and progressed following their last regimen. A performance status of at least 60% on the Karnofsky Scale and an anticipated survival of at least 3 months were also required, as was an absolute granulocyte count of >1500x10 9 /L and a platelet count of >100,000x10 9 /L within 14 days of study entry. Subjects were excluded if they had more than an average of 25% of the intratrabecular marrow space involved by lymphoma in bone marrow biopsy specimens as assessed microscopically within 42 days of study entry. Subjects who received cytotoxic chemotherapy, radiation therapy, or cytokine treatment within 4 weeks prior to study entry (6 weeks for nitrosourea compounds), or who exhibited persistent clinical evidence of toxicity were also excluded as were subjects with prior malignancies (other than lymphoma) except for adequately-treated skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease-free for 5 years. Number of Subjects BEX104505: Planned, N 40 Randomized, N 41 Completed, n (%) 38 (93%) a Total Number Subjects Withdrawn from BEX104505, N (%) 41 (100) Lost to follow-up 3(7) Received alternative therapy 1 (2) Progressive disease 27 (66) Died 1 (2) Other 9 (22) Number of Subjects BEX104528: Enrolled in BEX from BEX Total Subjects Withdrawn from BEX (100) Lost to follow-up 1 (6) Died 8 (44) Other (completed 10 years follow-up) 9 (50) Demographics N (ITT population) 41 Females:Males 21:20 Mean age, years (SD) 58.2 (11.4) White, n (%) 41 (100) Dosing Summary Tositumomab: Therapeutic Dose Received dosimetric and therapeutic dose, n 40 Days from dosimetric dose to therapeutic dose, median 8.0 Iodine I 131 tositumomab dose (mg): Therapeutic (hot dose), 35.0 median Administered iodine I-131 tositumomab activity (mci), median 95.1 (49 145) (range) Was infusion rate adjusted? n (%) Yes 0 No 40 (100) Whole Body Dose 2

3 N (15) 66 1 (3) (83) Primary Efficacy Results: Investigator-assessed determination of the response rate (CR+CCR+PR), n (%) 31 (76%) Summary of Response Data, by ITT n (%) [95% CI] Unconfirmed Responses Unconfirmed response (CRu+CCRu+PRu) 31 (76) [62, 89] Unconfirmed complete response (CRu) 16 (39) [24, 54] Unconfirmed complete clinical response (CCRu) 4 (10) [1, 19] Unconfirmed partial response (PRu) 11 (27) [13, 40] Not evaluable for response 1 Confirmed Responses, n (%) [95% CI] Confirmed response (CR+CCR+PR) 22 (54) [38, 69] Complete response (CR) 14 (34) [20, 49] Confirmed complete response (CCR) 3 (7) [0, 15] Confirmed partial response (PR) 4 (10) [1, 19] Not evaluable for response 6 Secondary Outcome Variables: Duration of confirmed response (CR+CCR+PR), responders, 46.4 (15.2, Not Reached) months, median (95% CI) Time to progression, all subjects, months, median (95% CI) 12.6 (6.1, 29.9) Time-to-treatment failure, all subjects, months, median (95% CI) 9.5 (6.0, 26.9) Overall survival, all subjects, months, median (95% CI) 74.5 (34.9, 121.5) Most Frequent Adverse Events On-Therapy ANY EVENT 40 (98%) [37] ANC <1000 cells/mm 3 18 (44%) [18] Platelets <50,000 cells/mm 3 15 (37%) [15] WBC <2000 cells/mm 3 14 (34%) [14] Nausea 13 (32%) [12] Thrombocytopenia 11 (27%) [11] Fatigue 8 (20%) [6] Anemia 7 (17%) [7] Cough 7 (17%) [4] Headache 7 (17%) [4] Lethargy 7 (17%) [6] Pyrexia 7 (17%) [6] Upper respiratory tract Infection 6 (15%) [3] Back pain 5 (12%) [2] Chills 5 (12%) [5] Constipation 5 (12%) [3] Hypothyroidism b 5 (12%) [4] Vomiting 5 (12%) [3] Edema peripheral 4 (10%) [0] Oropharyngeal pain 4 (10%) [4] Pain 4 (10%) [3] 3

4 Pain in extremity 4 (10%) [1] Rash 4 (10%) [4] All Serious Adverse Events (fatal and non-fatal) - On-Therapy ANY EVENT 13 (32) [13] Anemia 6 (15) [6] Thrombocytopenia 6 (15) [6] Myelodysplastic syndrome 3 (7) [3] Lower respiratory tract infection 2 (5) [ 2] Pancytopenia 2 (5) [ 2] Pneumonia 2 (5) [ 2] Pyrexia 2 (5) [ 2] Febrile neutropenia 1 (2) [ 1] Haematuria 1 (2) [ 1] Haemophilus infection 1 (2) [ 1] Hepatic failure 1 (2) [ 1] Herpes simplex 1 (2) [ 1] Herpes zoster 1 (2) [ 1] Hypercalcaemia 1 (2) [ 1] Neutropenia 1 (2) [ 1] Neutropenic sepsis 1 (2) [ 1] Pleural effusion 1 (2) Radiculitis brachial 1 (2) [ 1] Renal failure chronic 1 (2) [ 1] Respiratory tract infection 1 (2) [ 1] Fatal Serious AEs ANY FATAL EVENT 5 (12%) [5] Myelodysplastic syndrome 2 (5) [2] Hepatic failure 1 (2) [1] Hypercalcemia 1 (2) [1] Pneumonia 1 (2) [1] Renal failure chronic 1 (2) [1] Human Anti-Murine Antibody (HAMA) n (%) Number evaluable for HAMA 41 (100) Number not evaluable 0 Positive at baseline 0 No baseline or follow-up 0 Conversion to HAMA positivity Positive 4 (10) Negative 37 (90) Time to HAMA positivity from dosimetric dose, median days 112 (12 264) (range) Thyroid function b Number evaluable for thyroid evaluations, n (%) 36 (88) Elevated TSH post therapy, n (%) 9 (25) c Hypothyroidism, n (%) 3 (8) Time to hypothyroidism from dosimetric dose, days 192, 475, 671 4

5 a. Nine subjects completed the 10 years of follow-up in Study BEX b. Four subjects had elevated TSH levels or hypothyroidism at baseline. c. Three of 9 subjects with elevated TSH also developed hypothyroidism. Conclusions: Tositumomab and iodine I-131 tositumomab resulted in a 54% confirmed overall response rate, including a complete response rate (CR+CCR) of 41%, in subjects with 1st or 2nd relapsed indolent or transformed non-hodgkin's B-cell lymphoma. At the conclusion of 10 year follow up, the median duration of response for all confirmed responders was 46.4 months. The median overall survival was 74.5 months for all subjects. Hematologic toxicity included reduced neutrophil count (44%), platelet count (37%), white blood cell count (34%), and anemia (17%). Four subjects developed HAMA positivity within days after receiving the dosimetric dose. Myelodysplastic syndrome was observed in 3 (7%) subjects, and no other second cancers were observed. Three subjects developed hypothyroidism, and 6 additional subjects had elevated TSH levels after treatment but were not reported to have hypothyroidism due primarily to an elevated TSH level or known hypothyroidism at baseline. Thus, tositumomab and iodine I-131 tositumomab achieved durable responses, including complete responses, in patients with 1st or 2nd relapsed indolent or transformed B-cell NHL. 5

Study No.: Title: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Dosimetric Dose: 450 mg of TST infused over 70 minutes (inclusive of a 10-minute flush) immediately followed by 35

Dosimetric Dose: 450 mg of TST infused over 70 minutes (inclusive of a 10-minute flush) immediately followed by 35 The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

CLINICAL RESEARCH RESULTS FROM THE ANNUAL MEETINGS OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY AND THE SOCIETY OF NUCLEAR MEDICINE

CLINICAL RESEARCH RESULTS FROM THE ANNUAL MEETINGS OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY AND THE SOCIETY OF NUCLEAR MEDICINE FOR IMMEDIATE RELEASE CLINICAL RESEARCH RESULTS FROM THE ANNUAL MEETINGS OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY AND THE SOCIETY OF NUCLEAR MEDICINE Results of Studies of BEXXAR TM Therapy Show Promise

More information

Study No: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Bendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma

Bendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma Bendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma Kahl BS et al. Cancer 2010;116(1):106-14. Introduction > Bendamustine is a novel alkylating

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: TAG IDAG Objectives:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: TAG IDAG Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

RADIOIMMUNOCONJUGATES

RADIOIMMUNOCONJUGATES RADIOIMMUNOCONJUGATES TOSITUMOMAB (BEXXAR ) I. MECHANISM OF ACTION Tositumomab and Iodine I 131 tositumomab is an antineoplastic radioimmunotherapeutic monoclonal antibody-based regimen composed of the

More information

Strategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL

Strategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL New Evidence reports on presentations given at ASH 2009 Strategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL From ASH 2009: Non-Hodgkin

More information

This was a multicenter study conducted at 11 sites in the United States and 11 sites in Europe.

This was a multicenter study conducted at 11 sites in the United States and 11 sites in Europe. Protocol CAM211: A Phase II Study of Campath-1H (CAMPATH ) in Patients with B- Cell Chronic Lymphocytic Leukemia who have Received an Alkylating Agent and Failed Fludarabine Therapy These results are supplied

More information

To report SUSPECTED ADVERSE REACTIONS, contact GlaxoSmithKline at or FDA at FDA-1088 or

To report SUSPECTED ADVERSE REACTIONS, contact GlaxoSmithKline at or FDA at FDA-1088 or HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use BEXXAR safely and effectively. See full prescribing information for BEXXAR. BEXXAR (tositumomab and

More information

Targeted Radioimmunotherapy for Lymphoma

Targeted Radioimmunotherapy for Lymphoma Targeted Radioimmunotherapy for Lymphoma John Pagel, MD, PhD Fred Hutchinson Cancer Center Erik Mittra, MD, PhD Stanford Medical Center Brought to you by: Financial Disclosures Disclosures Erik Mittra,

More information

BR is an established treatment regimen for CLL in the front-line and R/R settings

BR is an established treatment regimen for CLL in the front-line and R/R settings Idelalisib plus bendamustine and rituximab (BR) is superior to BR alone in patients with relapsed/refractory CLL: Results of a phase III randomized double-blind placebo-controlled study Andrew D. Zelenetz,

More information

GSK Clinical Study Register

GSK Clinical Study Register In February 2013, GlaxoSmithKline (GSK) announced a commitment to further clinical transparency through the public disclosure of GSK Clinical Study Reports (CSRs) on the GSK Clinical Study Register. The

More information

ZEVALIN (ibritumomab tiuxetan) Information for Authorized Users and Administration Facilities

ZEVALIN (ibritumomab tiuxetan) Information for Authorized Users and Administration Facilities 0133-049104 ZEVALIN (ibritumomab tiuxetan) Information for Authorized Users and Administration Facilities Please see slides 3-7 for BOXED WARNINGS and Important Safety Information. Please see full Prescribing

More information

Background CPX-351. Lancet J, et al. J Clin Oncol. 2017;35(suppl): Abstract 7035.

Background CPX-351. Lancet J, et al. J Clin Oncol. 2017;35(suppl): Abstract 7035. Overall Survival (OS) With Versus in Older Adults With Newly Diagnosed, Therapy-Related Acute Myeloid Leukemia (taml): Subgroup Analysis of a Phase 3 Study Abstract 7035 Lancet JE, Rizzieri D, Schiller

More information

Sponsor / Company: Sanofi Drug substance(s): Docetaxel (Taxotere )

Sponsor / Company: Sanofi Drug substance(s): Docetaxel (Taxotere ) These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):

More information

CLINICAL STUDY REPORT SYNOPSIS

CLINICAL STUDY REPORT SYNOPSIS CLINICAL STUDY REPORT SYNOPSIS Document No.: EDMS-PSDB-5412862:2.0 Research & Development, L.L.C. Protocol No.: R115777-AML-301 Title of Study: A Randomized Study of Tipifarnib Versus Best Supportive Care

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace

More information

Sponsor / Company: Sanofi Drug substance(s): SAR (iniparib)

Sponsor / Company: Sanofi Drug substance(s): SAR (iniparib) These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):

More information

This was a multi-center study conducted at 44 study centers. There were 9 centers in the United States and 35 centers in Europe.

This was a multi-center study conducted at 44 study centers. There were 9 centers in the United States and 35 centers in Europe. Protocol CAM307: A Phase 3 Study to Evaluate the Efficacy and Safety of Frontline Therapy with Alemtuzumab (Campath ) vs Chlorambucil in Patients with Progressive B-Cell Chronic Lymphocytic Leukemia These

More information

Digital Washington University School of Medicine. Russell Schilder Fox Chase Comprehensive Cancer Center. Arturo Molina Biogen Idec

Digital Washington University School of Medicine. Russell Schilder Fox Chase Comprehensive Cancer Center. Arturo Molina Biogen Idec Washington University School of Medicine Digital Commons@Becker Open Access Publications 2004 Follow-up results of a phase II study of ibritumomab tiuetan radioimmunotherapy in patients with relapsed or

More information

ABC/3TC/ZDV ABC PBO/3TC/ZDV

ABC/3TC/ZDV ABC PBO/3TC/ZDV The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No Title : Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment:

Study No Title : Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

DYNAMO: A PHASE 2 STUDY OF DUVELISIB IN PATIENTS WITH REFRACTORY INDOLENT NON HODGKIN LYMPHOMA

DYNAMO: A PHASE 2 STUDY OF DUVELISIB IN PATIENTS WITH REFRACTORY INDOLENT NON HODGKIN LYMPHOMA DYNAMO: A PHASE 2 STUDY OF DUVELISIB IN PATIENTS WITH REFRACTORY INDOLENT NON HODGKIN LYMPHOMA Ian Flinn, CB Miller, KM Ardeshna, S Tetreault, SE Assouline, PL Zinzani, J Mayer, M Merli, SD Lunin, AR Pettitt,

More information

BEXXAR Tositumomab and Iodine I 131 Tositumomab

BEXXAR Tositumomab and Iodine I 131 Tositumomab BEXXAR Tositumomab and Iodine I 131 Tositumomab WARNINGS Hypersensitivity Reactions, including Anaphylaxis: Serious hypersensitivity reactions, including some with fatal outcome, have been reported with

More information

Clinical Trial Results Database Page 1

Clinical Trial Results Database Page 1 Page 1 Sponsor Novartis UK Limited Generic Drug Name Letrozole/FEM345 Therapeutic Area of Trial Localized ER and/or PgR receptor positive breast cancer Study Number CFEM345EGB07 Protocol Title This study

More information

Study No.:MPX Title: Rationale: Phase: IIB Study Period: Study Design: Centres: Indication: Treatment: Objectives:

Study No.:MPX Title: Rationale: Phase: IIB Study Period: Study Design: Centres: Indication: Treatment: Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

BESPONSA (inotuzumab ozogamicin)

BESPONSA (inotuzumab ozogamicin) BESPONSA (inotuzumab ozogamicin) Fact Sheet BESPONSA (inotuzumab ozogamicin) is an antibody-drug conjugate (ADC) composed of a monoclonal antibody (mab) targeting CD22, a cell surface antigen expressed

More information

Update: New Treatment Modalities

Update: New Treatment Modalities ASH 2008 Update: New Treatment Modalities ASH 2008: Update on new treatment modalities GA101 Improves tumour growth inhibition in mice and exhibits a promising safety profile in patients with CD20+ malignant

More information

Product: Blinatumomab Clinical Study Report: MT Date: 11 July 2014 Page 1

Product: Blinatumomab Clinical Study Report: MT Date: 11 July 2014 Page 1 Date: 11 July 2014 Page 1. 2. SYNOPSIS Name of Sponsor: Amgen Research (Munich) GmbH Name of Finished Name of Active Ingredient: Blinatumomab, a murine recombinant single-chain antibody derivative that

More information

UMEC/VI vs. UMEC in subjects who responded to UMEC UMEC/VI vs. VI in subjects who responded to VI

UMEC/VI vs. UMEC in subjects who responded to UMEC UMEC/VI vs. VI in subjects who responded to VI The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Idelalisib in the Treatment of Chronic Lymphocytic Leukemia

Idelalisib in the Treatment of Chronic Lymphocytic Leukemia Idelalisib in the Treatment of Chronic Lymphocytic Leukemia Jacqueline C. Barrientos, MD Assistant Professor of Medicine Hofstra North Shore LIJ School of Medicine North Shore LIJ Cancer Institute CLL

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Scottish Medicines Consortium

Scottish Medicines Consortium Scottish Medicines Consortium ibritumomab tiuxetan (Zevalin ) No. (171/05) Schering Health Care Ltd 8 April 2005 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product

More information

GSK Medicine: Study Number:

GSK Medicine: Study Number: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

NASDAQ: TGTX Jefferies Healthcare Conference June 2015

NASDAQ: TGTX Jefferies Healthcare Conference June 2015 NASDAQ: TGTX Jefferies Healthcare Conference June 2015 Forward Looking Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation

More information

Betalutin for the treatment of recurrent indolent NHL: new insights. Dr. Arne Kolstad 22 November 2017

Betalutin for the treatment of recurrent indolent NHL: new insights. Dr. Arne Kolstad 22 November 2017 Betalutin for the treatment of recurrent indolent NHL: new insights Dr. Arne Kolstad 22 November 2017 Betalutin, a new anti-cd37 antibody radionuclide conjugate (ARC) lutetium-177: Beta-particle emitting

More information

Abstract 861. Stein AS, Topp MS, Kantarjian H, Gökbuget N, Bargou R, Litzow M, Rambaldi A, Ribera J-M, Zhang A, Zimmerman Z, Forman SJ

Abstract 861. Stein AS, Topp MS, Kantarjian H, Gökbuget N, Bargou R, Litzow M, Rambaldi A, Ribera J-M, Zhang A, Zimmerman Z, Forman SJ Treatment with Anti-CD19 BiTE Blinatumomab in Adult Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (R/R ALL) Post-Allogeneic Hematopoietic Stem Cell Transplantation Abstract

More information

(212) (347)

(212) (347) EMBARGOED FOR MONDAY, JUNE 21, 2010: 3:00 P.M. EST For immediate release: June 21, 2010 Media Contact: Curtis Allen (212) 733-2096 (347) 443-5252 Investors Contact: Suzanne Harnett (212) 733-8009 Pfizer

More information

Study No: Title: Rationale: . Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No: Title: Rationale: . Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

HM2008/00566/00. study and to obtain clinical experience with the use of this drug. Primary Outcome/Efficacy Variable(s): <Pharmacokinetics>

HM2008/00566/00. study and to obtain clinical experience with the use of this drug. Primary Outcome/Efficacy Variable(s): <Pharmacokinetics> The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

MabThera. SC. The wait is over. MabThera delivered in just 5 minutes. SC= subcutaneous injection

MabThera. SC. The wait is over. MabThera delivered in just 5 minutes. SC= subcutaneous injection MabThera SC. The wait is over. MabThera delivered in just 5 minutes Abbreviated Prescribing Information MabThera 1400 mg solution for subcutaneous (SC) injection (Rituximab) Indications: Indicated in adults

More information

Sponsor/Company: sanofi-aventis Drug substance: Elitek/Fasturtec (rasburicase, SR29142)

Sponsor/Company: sanofi-aventis Drug substance: Elitek/Fasturtec (rasburicase, SR29142) These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor/Company: sanofi-aventis Drug

More information

Improving Response to Treatment in CLL with the Addition of Rituximab and Alemtuzumab to Chemoimmunotherapy

Improving Response to Treatment in CLL with the Addition of Rituximab and Alemtuzumab to Chemoimmunotherapy New Evidence reports on presentations given at ASH 2009 Improving Response to Treatment in CLL with the Addition of Rituximab and Alemtuzumab to Chemoimmunotherapy From ASH 2009: Chronic Lymphocytic Leukemia

More information

Bendamustine for relapsed follicular lymphoma refractory to rituximab

Bendamustine for relapsed follicular lymphoma refractory to rituximab LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Bendamustine for relapsed follicular lymphoma refractory to rituximab Bendamustine for relapsed follicular lymphoma refractory to rituximab Contents Summary 1

More information

WARNING, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS,

WARNING, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, Celgene Corporation 86 Morris Avenue Summit, New Jersey 07901 Tel 908-673-9000 Fax 908-673-9001 October 2012 NEW Indication Announcement for ABRAXANE for Injectable Suspension (paclitaxel protein-bound

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

This was a multinational, multicenter study conducted at 14 sites in both the United States (US) and Europe (EU).

This was a multinational, multicenter study conducted at 14 sites in both the United States (US) and Europe (EU). These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. NAME OF SPONSOR/COMPANY: Genzyme Corporation,

More information

RADIOIMMUNOTHERAPY FOR TREATMENT OF NON- HODGKIN S LYMPHOMA

RADIOIMMUNOTHERAPY FOR TREATMENT OF NON- HODGKIN S LYMPHOMA RADIOIMMUNOTHERAPY FOR TREATMENT OF NON- HODGKIN S LYMPHOMA Pier Luigi Zinzani Institute of Hematology and Medical Oncology L. e A. Seràgnoli University of Bologna, Italy Slovenia, October 5 2007 Zevalin

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Product: Blinatumomab (AMG 103) Clinical Study Report: MT Date: 19 April 2013 Page 2 of 9510

Product: Blinatumomab (AMG 103) Clinical Study Report: MT Date: 19 April 2013 Page 2 of 9510 Date: 19 April 2013 Page 2 of 9510 2. SYNOPSIS Name of Sponsor: Amgen Research (Munich), formerly Micromet AG/Micromet GmbH, Staffelseestrasse 2, 81477 Munich, Germany Name of Finished Product: Blinatumomab

More information

Clinical Commissioning Policy Proposition: Bortezomib for relapsed/refractory mantle cell lymphoma

Clinical Commissioning Policy Proposition: Bortezomib for relapsed/refractory mantle cell lymphoma Clinical Commissioning Policy Proposition: Bortezomib for relapsed/refractory mantle cell lymphoma Reference: NHS England xxxxx 1 First published: TBC Prepared by NHS England Specialised Services Clinical

More information

ASH POSTER: LYMRIT UPDATE

ASH POSTER: LYMRIT UPDATE ASH POSTER: LYMRIT 37-01 UPDATE DECEMBER 2018 EDUARDO BRAVO, CEO LISA ROJKJAER, MD, CMO Nordic Nanovector ASA Kjelsåsveien 168 B, 0884 Oslo, Norway www.nordicnanovector.com IR contact: ir@nordicnanovector.com

More information

PFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI

PFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

M Y ELO I D D I FFER ENTIATI O N OPENS UP THE POSSIBILITIES

M Y ELO I D D I FFER ENTIATI O N OPENS UP THE POSSIBILITIES IDHIFA (enasidenib) is indicated for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an

More information

New Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders

New Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders New Evidence reports on presentations given at EHA/ICML 2011 Bendamustine in the Treatment of Lymphoproliferative Disorders Report on EHA/ICML 2011 presentations Efficacy and safety of bendamustine plus

More information

Myelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Post-HCT Data

Myelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Post-HCT Data Instructions for Myelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Post-HCT Data (Form 2114) This section of the CIBMTR Forms Instruction Manual is intended to be a resource for completing the Myelodysplasia/Myeloproliferative

More information

Disclosures for Dr. Peter Borchmann 48 th ASH Annual meeting, Orlando, Florida

Disclosures for Dr. Peter Borchmann 48 th ASH Annual meeting, Orlando, Florida Phase II Study of Pixantrone in Combination with Cyclophosphamide, Vincristine, and Prednisone (CPOP) in Patients with Relapsed Aggressive Non-Hodgkin s Lymphoma P Borchmann Universitaet de Koeln, Koeln,

More information

This is a controlled document and therefore must not be changed

This is a controlled document and therefore must not be changed AZACITIDINE NICE TA218 Treatment of adults not eligible for haematopoietic stem cell transplantation who have: Intermediate-2 and high-risk MDS according to the International Prognostic Scoring System

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Analysis of safety The analysis was performed on the Total Vaccinated cohort.

Analysis of safety The analysis was performed on the Total Vaccinated cohort. The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Title A Phase II study of oral LBH589 in adult patients with refractory cutaneous T-Cell lymphoma

Title A Phase II study of oral LBH589 in adult patients with refractory cutaneous T-Cell lymphoma Sponsor Novartis Generic Drug Name Panobinostat Therapeutic Area of Trial Refractory cutaneous T-Cell lymphoma Approved Indication Investigational drug Protocol Number CLBH589B2201 Title A Phase II study

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objective: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objective: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Bendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma

Bendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma Bendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma Friedberg JW et al. Proc ASH 2009;Abstract 924. Introduction > Bendamustine (B)

More information

Clinical Commissioning Policy: Bortezomib for relapsed/refractory mantle cell lymphoma (all ages) NHS England Reference: P

Clinical Commissioning Policy: Bortezomib for relapsed/refractory mantle cell lymphoma (all ages) NHS England Reference: P Clinical Commissioning Policy: Bortezomib for relapsed/refractory mantle cell lymphoma (all ages) NHS England Reference: 1735P NHS England INFORMATION READER BOX Directorate Medical Operations and Information

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: Study No.: 29060/717 Title: A Double-Blind, Placebo-Controlled, 3-Arm, Fixed-Dose Study of CR Intermittent Dosing (12.5 mg and 25 mg) for Premenstrual Dysphoric Disorder Rationale: In most trials investigating

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Tositumomab and iodine I 131 tositumomab (Bexxar ) Corixa Corporation; marketed by GlaxoSmithKline 1

Tositumomab and iodine I 131 tositumomab (Bexxar ) Corixa Corporation; marketed by GlaxoSmithKline 1 Generic (Trade Name): Manufacturer: Tositumomab and iodine I 131 tositumomab (Bexxar ) Corixa Corporation; marketed by GlaxoSmithKline 1 NO. 64 OCTOBER 2005 Indication: Current Regulatory Status: In the

More information

Leukine. Leukine (sargramostim) Description

Leukine. Leukine (sargramostim) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.85.08 Subject: Leukine Page: 1 of 5 Last Review Date: September 15, 2017 Leukine Description Leukine

More information

Manufacturer: Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.

Manufacturer: Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc. Brand Name: Mylotarg Generic Name: gentuzumab ozogamicin Manufacturer: Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc. Drug Class: CD33-directed antibody-drug conjugate Uses: Labeled Uses: Newly-diagnosed

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the

More information

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Ibritumomab Tiuxetan in Lymphoma: A Clinical Practice Guideline

Ibritumomab Tiuxetan in Lymphoma: A Clinical Practice Guideline Evidence-based Series #6-17: Section 1 Ibritumomab Tiuxetan in Lymphoma: A Clinical Practice Guideline M. Cheung, A.E. Haynes, A. Stevens, R.M. Meyer, K. Imrie, and the members of the Hematology Disease

More information

A Quality Initiative of the Program in Evidence-based Care (PEBC), Cancer Care Ontario (CCO) Iodine-131 Tositumomab in Lymphoma

A Quality Initiative of the Program in Evidence-based Care (PEBC), Cancer Care Ontario (CCO) Iodine-131 Tositumomab in Lymphoma Evidence-based Series 6-19 EDUCATION AND INFORMATION 2013 A Quality Initiative of the Program in Evidence-based Care (PEBC), Cancer Care Ontario (CCO) Iodine-131 Tositumomab in Lymphoma The Hematology

More information

Commercial Drug Ordering Overview

Commercial Drug Ordering Overview Commercial Drug Ordering Overview The following instruction is provided to assist in the process of ordering ZEVALIN (ibritumomab tiuxetan). STEP 1 Treating Site Place order to the radiopharmacy Specify

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Analysis of immunogenicity

Analysis of immunogenicity The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

FIRST RESULTS OF NEW DATA OF ABRAXANE IN COMBINATION WITH ATEZOLIZUMAB PRESENTED AT ESMO 2018

FIRST RESULTS OF NEW DATA OF ABRAXANE IN COMBINATION WITH ATEZOLIZUMAB PRESENTED AT ESMO 2018 FIRST RESULTS OF NEW DATA OF ABRAXANE IN COMBINATION WITH ATEZOLIZUMAB PRESENTED AT ESMO 2018 IMpassion130 reports first positive Phase III study results for a chemotherapy/immunotherapy (ABRAXANE plus

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objective: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objective: Primary Outcome/Efficacy Variable: Studies listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

[ NASDAQ: MEIP ] Analyst & Investor Event December 8, 2014

[ NASDAQ: MEIP ] Analyst & Investor Event December 8, 2014 [ NASDAQ: MEIP ] Analyst & Investor Event December 8, 2014 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements. Actual events or results may

More information

Drug Niraparib Olaparib

Drug Niraparib Olaparib Dear NCCN Value Pathway Committee, We are making this submission to provide information that we believe is relevant for developing NCCN Categories of Preference for the use of PARP inhibitors in recurrent

More information

Update: Chronic Lymphocytic Leukemia

Update: Chronic Lymphocytic Leukemia ASH 2008 Update: Chronic Lymphocytic Leukemia Improving Patient Response to Treatment with the Addition of Rituximab to Fludarabine-Cyclophosphamide ASH 2008: Update on chronic lymphocytic leukemia CLL-8

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Docetaxel. Class: Antineoplastic agent, Antimicrotubular, Taxane derivative.

Docetaxel. Class: Antineoplastic agent, Antimicrotubular, Taxane derivative. Docetaxel Class: Antineoplastic agent, Antimicrotubular, Taxane derivative. Indications: -Breast cancer: -Non small cell lung cancer -Prostate cancer -Gastric adenocarcinoma _Head and neck cancer Unlabeled

More information

MDS-004 Study: REVLIMID (lenalidomide) versus Placebo in Myelodysplastic Syndromes with Deletion (5q) Abnormality

MDS-004 Study: REVLIMID (lenalidomide) versus Placebo in Myelodysplastic Syndromes with Deletion (5q) Abnormality MDS-4 Study: REVLIMID (lenalidomide) versus Placebo in Myelodysplastic Syndromes with Deletion (5q) Abnormality TABLE OF CONTENTS Section 1. Executive Summary Section 2. Background Section

More information

ICML BETALUTIN LYMRIT STUDY UPDATE JUNE 14 TH, 2017

ICML BETALUTIN LYMRIT STUDY UPDATE JUNE 14 TH, 2017 ICML 2017 - BETALUTIN LYMRIT 37-01 STUDY UPDATE JUNE 14 TH, 2017 Disclaimer This presentation may contain certain forward-looking statements and forecasts based on uncertainty, since they relate to events

More information

Leukine. Leukine (sargramostim) Description

Leukine. Leukine (sargramostim) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Leukine Page: 1 of 6 Last Review Date: November 30, 2018 Leukine Description Leukine (sargramostim)

More information

Λουκάς Κοντοβίνης, παθολόγος - ογκολόγος.

Λουκάς Κοντοβίνης, παθολόγος - ογκολόγος. Λουκάς Κοντοβίνης, παθολόγος - ογκολόγος l.kontovinis@oncomedicare.com Nuclear Medicine Review 2011, 14, 2: 96 104 N Engl J Med 2004;350:1655-64 Nuclear Medicine Review 2011, 14, 2: 96 104 N Engl J Med

More information

ZYDELIG PBS. (idelalisib) RETHINK WHAT S POSSIBLE... LISTED 1

ZYDELIG PBS. (idelalisib) RETHINK WHAT S POSSIBLE... LISTED 1 RETHINK WHAT S POSSIBLE... ZYDELIG (idelalisib) PBS LISTED 1 st 1 September 2017 ZYDELIG a first-in-class oral PI3Kδ inhibitor is PBS listed from 1 st September 2017 for the treatment of: Double-refractory

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objective: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objective: Primary Outcome/Efficacy Variable: Studies listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Center: Indication: Treatment: Objective: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Center: Indication: Treatment: Objective: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period Study Design: Centres: Indication: Treatment: Objectives:

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period Study Design: Centres: Indication: Treatment: Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

PFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI

PFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.

More information

GSK Medicine Study Number: Title: Rationale Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:

GSK Medicine Study Number: Title: Rationale Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: The study listed may include approved and nonapproved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information